Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for ...
Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...
Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...
Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently answered questions about. Answering a caller’s ...
See, LLY stock warrants your attention. Why? Because it offers monopoly-like high margins at a discounted price.
Eli Lilly (NYSE: LLY) is part of this group. On Sept. 16, the drugmaker announced plans to build a $5 billion facility in ...
Eli Lilly and Company is a Strong Buy due to strong growth in obesity and diabetes drugs and pipeline innovation. Learn more ...
Eli Lilly jumps to top 10% in quality rankings, showing strong fundamentals even as Trump pushes for weight loss drug price ...
Eli Lilly ( NYSE: LLY) has partnered with India's Cipla to market its weight-loss medication Tirzepatide under a new brand in ...
CDSCO allows Eli Lilly to withdraw Covid-19 indications of baricitinib: Gireesh Babu, New Delhi Saturday, October 25, 2025, 08:00 Hrs [IST] The Central Drugs Standard Control Orga ...
1don MSN
First Mounjaro, now Yurpeak: Eli Lilly ties up with Cipla to bring weight loss drug under new name
Under the agreement, Eli Lilly will continue to market tirzepatide under brand name Mounjaro, while Cipla will have the ...
"Lilly and Incyte to seek approval of alopecia JAK inhibitor in children" was originally created and published by Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback